SCHEMBL5162460

SCHEMBL5162460

CC(C)OC(=O)CC(=O)c1ncc[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HSPA5 P11021 1/20 0.37
TSHR P16473 2/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 1/20 0.35
BRAF P15056 1/20 0.34
HDAC1 Q13547 1/20 0.34
MAPT P10636 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
P2RY12 Q9H244 1/20 0.34
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTT P42858 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160052 0.83 NPC1 (0.44) NPC1RAB9AHSPA5KDM4EALDH1A1
SCHEMBL5161099 0.79 KDM4E (0.44) NPC1RAB9ATSHRKDM4EALDH1A1
SCHEMBL29163121 0.79 NPC1 (0.47) NPC1RAB9AHSPA5KDM4EALDH1A1
SCHEMBL5164159 0.78 NPC1 (0.40) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL11678609 0.75 NPC1 (0.45) NPC1RAB9AHSPA5ALDH1A1KMT2A
SCHEMBL31602536 0.75 NPC1 (0.45) NPC1RAB9AHSPA5KDM4EALDH1A1
SCHEMBL743343 0.74 NPC1 (0.43) NPC1RAB9AHSPA5KDM4EALDH1A1
SCHEMBL2321138 0.74
SCHEMBL5160738 0.73 NPC1 (0.44) NPC1RAB9AHSPA5KDM4EALDH1A1
SCHEMBL5162472 0.73 TSHR (0.43) NPC1RAB9ATSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO NPC1 2400/4885RAB9A 3428/4885HSPA5 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.